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ABSTRACT: The DDR1 receptor tyrosine kinase is activated
by matrix collagens and has been implicated in numerous
cellular functions such as proliferation, diﬀerentiation,
adhesion, migration, and invasion. Here we report the
discovery of a potent and selective DDR1 inhibitor, DDR1-
IN-1, and present the 2.2 Å DDR1 co-crystal structure. DDR1-
IN-1 binds to DDR1 in the ‘DFG-out’ conformation and
inhibits DDR1 autophosphorylation in cells at submicromolar
concentrations with good selectivity as assessed against a panel
of 451 kinases measured using the KinomeScan technology. We identiﬁed a mutation in the hinge region of DDR1, G707A, that
confers >20-fold resistance to the ability of DDR1-IN-1 to inhibit DDR1 autophosphorylation and can be used to establish what
pharmacology is DDR1-dependent. A combinatorial screen of DDR1-IN-1 with a library of annotated kinase inhibitors revealed
that inhibitors of PI3K and mTOR such as GSK2126458 potentiate the antiproliferative activity of DDR1-IN-1 in colorectal
cancer cell lines. DDR1-IN-1 provides a useful pharmacological probe for DDR1-dependent signal transduction.
T
he discoidin domain receptor (DDR) kinases bind to
several collagens and have been shown to be key regulators
of cellular morphogenesis, diﬀerentiation, proliferation, adhe-
sion, migration, and invasion.
1 There are two types of DDR
kinases, DDR1 and DDR2, which are characterized by an
approximately 155-aa discoidin homology domain in the
extracellular region of the protein. DDR1 is primarily expressed
in epithelial cells of a variety of tissues, whereas DDR2 is
expressed in interstitial cells. DDR1 was originally identiﬁed in a
screen for tyrosine kinase proteins expressed in human
malignancies.
2 Recent studies have reported altered expression
of DDR1 in human tumors, including lung, esophagous, breast,
ovary, and pediatric brain cancers, suggesting a potential role for
DDR1 in tumor progression.
3−6 Moreover, the elevated
expression of DDR1 in a number of fast-growing invasive
tumors has suggested that this matrix-activated RTK may be
involved in the proliferation of and stromal invasion by tumor
cells.
7 The precise mechanisms by which this receptor may
contribute to oncogenesis is unknown; however, given its
important role in transmitting signals from the extracellular
matrix (ECM), it has been postulated that it may act as a critical
regulator of cell proliferation, adhesion, migration, and
subsequent tumor metastasis.
8 Recently, DDR1 was identiﬁed
as one of several major activated tyrosine kinases carrying
somatic mutations in non-small cell lung tumors as well as in
acute myeloid leukemia.
9,10 Moreover, through a chemical
proteomics approach, DDR1 was identiﬁed as a previously
unanticipated target of imatinib, a clinically approved multi-
targeted inhibitor of Bcr-Abl, c-Kit, and PDGFR,
11 which raises
the possibility that inhibition of DDR1 could contribute to a
subset of pharmacological eﬀects of the drug. Overexpression of
DDR1 in several human cancer cell lines enhanced anchorage-
independent growth and tumorigenic potential in nude mice.
12
In addition, knock-down of DDR1 may suppress the tumor-
igensis in vitro and in vivo.
12 The identity of direct DDR1
substrates and downstream eﬀectors is currently unknown.
DDR1 is a direct p53 transcriptional target and is essential for
survival of wild-type p53 cells when challenged with genotoxic
stress, suggesting that inhibition of DDR1 function may provide
a potential approach to selectively enhance treatment of such
tumors.
13 In order to determine the pharmacological con-
sequencesofacuteinhibitionofDDR1kinaseactivityinavariety
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inhibitors.
It has been reported that the clinically approved BCR-ABL
kinaseinhibitorsimatinib,nilotinib,and dasatinibarealsopotent
inhibitors of DDR1 and DDR2.
14,15 However, these drugs
potently target a number of other important kinases, making
them diﬃcult to use as pharmacological probes of DDR1-
dependent cellular phenomena.
16 Recently Ding et al. reported
the development of pyrazolopyrimidine derivatives that inhibit
DDR1 kinase activity with an IC50 of 6.8 nM and exhibit good
selectivity using the KinomeScan approach (S(10) = 0.008 at 0.1
μM).
17 Noting imatinib and nilotinib as typical type II kinase
inhibitors, we used this structural information in conjunction
withageneralpharmacophoremodelfortypeIIkinaseinhibitors
to develop a library of potential kinase inhibitors (Figure 1A).
18
This pharmacophore model divides the inhibitors into three
sections: a ‘head’ hinge interacting motif that occupies the
adenine portion of the ATP-pocket, a ‘linker’motif that traverses
the area proximal to the ‘gatekeeper’ position, and a ‘tail’ motif
thatoccupiestheregioncreatedbytheﬂipofthe‘DFG’sequence
of the activation loop. A collection of close to 100 type II
inhibitorscreatedbythisapproachwasscreenedacrossapanelof
451 kinases using the KinomeScan approach, which resulted in
the identiﬁcation of DDR1-IN-1 and DDR1-IN-2 as two
chemotypes that possessed potent and selective binding to
DDR1 (Figure 1B).
We conﬁrmed the observed binding to DDR1 using an
enzymatic kinase assay employing the Lanthascreen technology.
In this assay DDR1-IN-1 exhibits an IC50 of 105 nM against
DDR1 and 413 nM against DDR2. DDR1-IN-2 exhibits an IC50
of47nMagainstDDR1and145nMagainstDDR2(Table1).In
order to determine whether these inhibitors could inhibit DDR1
kinaseactivityincells,wemeasuredtheirabilitytoblockcollagen
induced DDR1autophosphorylation in U2OS cells. DDR1-IN-1
and DDR1-IN-2 inhibited basal DDR1 autophosphorylation
withanEC50of86nMand9nM,respectively(Figure1C,D).To
Figure 1. Developing selective type II kinase inhibitors. (A) Docking imatinib into the X-ray co-crystal structure of DDR1. (B) Chemical structure of
DDR1-IN-1/2 andrepresentative developing rationale. (C)DDR1-IN-1 eﬃcacyon blockingDDR1 autophosphorylation. (D) DDR1-IN-2eﬃcacy on
blocking DDR1 autophosphorylation. (E) KinomeScanTreeSpot description of the DDR1-IN-1/2 selectivity proﬁle.
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activated DDR1, we compared the ability of the two compounds
toinhibitDDR1autophosphorylationincellsinthepresenceand
absence of collagen stimulation. Both DDR1-IN-1 and DDR1-
IN-2 demonstrated weaker inhibition of DDR1 autophosphor-
ylation in the absence of collagen stimulation (Supplemental
Figure 1).
DDR1-IN-1 exhibits excellent selectivity for DDR1 with a
selectivity score (S(1) at 1 μM) of 0.01 as assessed using the
KinomeScan approach with binding observed for ABL, KIT, and
PDGFRβ, none of which were conﬁrmed using enzymatic assays
(Figure 1E and Supplemental Tables 1 and 2). In contrast,
DDR1-IN-2 is considerably less selective with a selectivity score
(S(1) at 1 μM) of 0.07 and potential additional targets including
Abl, BLK, CSK, EGFR, LCK, and PDGFRβ (Supplemental
Tables 3 and 4).
Despite the excellent kinase selectivity observed for DDR1-
IN-1, there always remains the possibility that other unantici-
Table 1. Biochemical Characterization of DDR1-IN-1/2
IC50 (nM)
nilotinib imatinib DDR1-IN-1 DDR1-IN-2
DDR1 43 337 105 47.6
DDR2 0.5 675 413 145
Figure 2. Binding information of DDR1-IN-1/2 against DDR1. (A) X-ray co-crystal structure of DDR1-IN-1 with DDR1 kinase. (B) G707A mutation
rescuedtheDDR1-IN-1inhibitoryeﬀectagainstDDR1inU2OScellline.(C)G707AmutationrescuedtheDDR1-IN-2inhibitoryeﬀectagainstDDR1
in U2OS cell line. (D) DDR1-IN-2 docked into the DDR1 kinase. (E) DDR1-IN-2 docked into the DDR1 G707A mutation.
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therefore sought to develop an ‘inhibitor-resistant’ mutant of
DDR1 that could be used as a ‘chemical-genetic’ means to
evaluate inhibitor selectivity. To conﬁrm the inhibitor binding
mode and select the key drug-resistant amino acid residue, we
determined the 2.2 Å co-crystal structure of DDR1 in complex
withDDR1-IN-1,whichconﬁrmedthepresumedtypeIIbinding
mode (Figure 2A and Supplemental Table 5). As expected, two
hydrogen bonds formed in the hinge binding area with Met704
and Asp702. Glu672 in the c-Helix and Asp784 in DFG motif
formed two hydrogen bonds with the linker amide moiety. One
potential drug-resistant mutation site is the ‘gatekeeper’ residue
Thr701; indeedthecorresponding gatekeeper mutation inBCR-
ABL, PDGF, and c-KIT has been demonstrated to confer
resistance to type II inhibitors such as imatinib and nilotinib.
However, this mutation in DDR1 leads to a loss of enzymatic
activity (Supplemental Figure 2). We therefore chose to test an
alternativemutationinthehingeregion,G707A,wheremodeling
and previous eﬀorts have demonstrated that inhibitor resistance
can be conferred.
19 Introduction of G707A into DDR1 resulted
ina20-and100-foldincreaseintheEC50withwhichDDR1-IN-1
and DDR1-IN-2 could inhibit DDR1 autophosphorylation in
cells (Figure 2B,C).
19 Docking DDR1-IN-2 into the DDR1
crystal structure with a modeled G707A mutation suggested that
the side-chain methyl group of alanine would potentially clash
with the azaindole ring of DDR1-IN-2 (Figure 2D,E). In
addition,themodelsuggeststhatgatekeeperresidueThr701may
form a hydrogen bond with nitrogen between the “ Head” and
“Linker” region of DDR1-IN-2, which may explain its ability to
more potently inhibit DDR1 relative to DDR1-IN-1 (Figure
2D,A).
We next used DDR1-IN-1 and DDR1-IN-2 to assess the
consequences of inhibiting DDR1 activity in a panel of diﬀerent
cancer cell lines that have been reported to possess DDR1 gain-
of-function mutations and/or overexpression.
1 To our surprise,
the more selective DDR1 inhibitor, DDR1-IN-1, did not inhibit
proliferation below a concentration of 10 μM, while the
multitargeted inhibitor, DDR1-IN-2, inhibited the proliferation
of a variety of cell lines at single digit micromolar and lower
concentrations, although both inhibitors did aﬀect the
autophosphorylation of the DDR1 during the drug treatment
(Table 2 and Supplemental Figure 3). In order to assess whether
the antiproliferative potency of DDR1-IN-2 was a consequence
of inhibition of DDR1, we transiently expressed the G707A
DDR1mutationtoU2OScells.Introductionofthismutationdid
not change the antiproliferative potency of DDR1-IN-2
(Supplemental Figure 4 and Supplemental Table 6). These
results suggest that acute inhibition of DDR1 kinase activity is
insuﬃcient to inhibit the proliferation of these cancer cell lines
under the conditions investigated.
We next sought to identify which kinase targets might
potentiate the eﬀects of DDR1 inhibition. This would guide
potential combinatorial therapy and suggest what pathways
might dynamically compensate for acute loss of DDR1 signaling.
To accomplish this, we performed a 3-day combinatorial kinase
inhibitorscreeningwherewecombinedDDR1-IN-1inapairwise
fashion with 200 diﬀerent well characterized kinase inhibitors
(LINCS library, see: https://lincs.hms.harvard.edu) targeting a
variety of pathways. We selected the SNU-1040 cell line for the
combinatorial screen since it is one of the most resistant to both
DDR1-IN-1and2(GI50:>10μMand3.52μM,respectively,and
SupplementalFigure5).DDR1-IN-1wasﬁxedataconcentration
of 1 μM, which is suﬃcient to inhibit DDR1 autophosphor-
ylation. The combinatorial screen revealed a number of
inhibitors targeting kinases such as EGFR, Src, Cdk1, mTOR,
and PI3K that appeared to positively combine with DDR1-IN-1
to inhibit cell growth. A similar screen was performed with
DDR1-IN-2, which revealed inhibitors of 12 targets able to
positively combine with DDR1-IN-2. PI3K and mTOR
inhibitors were revealed by screening of a kinase inhibitor
chemicallibrarytopositivelycombinewithbothDDR1-IN-1and
DDR1-IN-2 (Figure 3A,B and Supplemental Tables 7 and 8).
Full dose−response curves were generated for DDR1-IN-1 and
DDR1-IN-2, both alone and in combination with GSK2126458
and AZD8055, respectively. These studies revealed positive
combination eﬀects between DDR1-IN-1 and GSK2126458 as
well as between DDR1-IN-2 and AZD8055. Calcusyn analysis of
the DDR1-IN-2+AZD8055 revealed synergy (Figure 3C,D,E).
Discussion. Receptor tyrosine kinases (RTKs) are critical
transducers of extracellular cues to intracellular signaling
networks that integrate and orchestrate key cellular decisions
such as migration, proliferation, diﬀerentiation, and survival.
20
Deregulation of the RTKs is often observed in pathological
associations such as cancers. Numerous mutations have been
reported in DDR1, but whether it may represent an attractive
anticancer target is currently unclear. In this paper we
implemented a focused medicinal chemistry library approach
todiscovertwonewpotentDDR1kinaseinhibitors.DDR1-IN-1
is a selective DDR1 kinase inhibitor that through kinome-wide
selectivity proﬁling and biochemical assay conﬁrmation was not
observed to target other protein kinases when used at
concentrations of less than 10 μM. DDR1-IN-2 is a more potent
DDR1 kinase inhibitor but also potently inhibits a number of
additional kinase targets. In addition, there were apparent eﬀects
on the downstream signaling of DDR1. However, the most
selective DDR1 kinase inhibitor DDR1-IN-1 does not seem to
have signiﬁcant antiproliferation eﬀects on DDR1 deregulated
cancer cell lines, whereas the multitarget inhibitor DDR1-IN-2
shows a more profound antigrowth eﬀect. This might indicate
that DDR1-IN-1 may be an incomplete inhibitor of DDR1-
mediatedsignalingperhapsbecauseotherkinasessuchastheSrc-
family of kinases, which are known to associate with DDR1 also
contribute to DDR1-dependent signaling.
21 The stronger
antiproliferative eﬀect of DDR1-IN-2 is likely a consequence of
its ability to potently inhibit several kinases other than DDR1.
Other multitargeted inhibitors such as imatinib, which inhibits
Abl, c-Kit, PDGFR, and DDR1, do not possess strongly
antiproliferative eﬀects, so it remains to be determined which
Table 2. DDR1-IN-1/2 Anti-proliferation Eﬀect on Cancer
Cell Lines
cell lines
a origin DDR1-IN-1 (μM) DDR1-IN-2 (μM)
HCT-116(OWT) colon 8.7 0.81
T47D(OWT) breast >10 1.11
A549(WT) lung >10 2.29
H1975(WT) lung >10 0.89
SaoS2(WT) sarcoma 8.14 0.39
SkBr3(WT) breast >10 3.07
SW480(OWT) colon >10 2.76
SNU-1040(OMT) colorectal >10 3.52
EJ(WT) uterus >10 4.60
SNU-449(OMT) HCC >10 1.10
aOWT = overexpression of wide type, WT = wide type, OMT =
overexpression of mutant type.
ACS Chemical Biology Letters
dx.doi.org/10.1021/cb400430t | ACS Chem. Biol. 2013, 8, 2145−2150 2148additional kinase targets of DDR1-IN-2 contribute to its
antiproliferative potency (Supplemental Figure 6). A combina-
torial kinase inhibitor screening revealed that inhibition of either
thePI3KormTORcanpotentiatetheeﬀectofDDR1inhibition.
These ﬁndings suggested that the DDR1 kinase activity alone
may be insuﬃcient to inhibit cell proliferation and that DDR1
directed therapy will need to be deployed in a combinatorial
format. Further investigation is required to determine whether
inhibition of DDR1 kinase activity can impact other phenomena
such as cell adhesion, migration, or invasion. Given the fact that
the pathological role of DDR1 is not yet understood, we believe
the new potent and selective inhibitors DDR1-IN-1/2 will serve
as useful pharmacological tools to help the dissect its functions
and lay the foundation for the development of DDR1 targeted
anticancer therapies.
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Figure3.CombinatorialScreeningofDDR1-IN-1/2withtheLINCSlibraryagainsttheSNU-1040cellline.(A)PositivehitswithDDR1-IN-1.CSF1R/
DDR1/EGFR/TIE1/PDGFR2 = WZ-4-145; mTOR = WYE-125132; Cdk1/CyclinB = CGP60474; Chk = PF477736; PI3K = PI103; PI3K/mTOR =
GSK2126458; Src/BCR-ABL = AP24534; EGFR = EKB-569; mTOR = Torin2. (B) Positive hits with DDR1-IN-2. CSF1R/DDR1/EGFR/TIE1/
PDGFR2 = WZ-4-145; mTOR = WYE-125132; CLK2/CNSK1E/FLT3/ULK1 = WZ3105; Akt1 = A443644; LRRK2 = XMD11-50; mTOR =
AZD8055; c-MET = ARQ197; CDK = BMS-387032; PI3K = GSK1059615; PLK1 = GW843682; MEK = AZD6244; mTOR = Torin2. (C)
CombinatorialeﬀectofDDR1-IN-1withGSK2126458.(D)SynergisticeﬀectofDDR1-IN-2withAZD8055.(E)Combinatorialeﬀectontheblockade
of signaling pathway factors.
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